GlassScriptPhysician profile
Nandhakumar Kanagarajan
NPI 1902819667
$13,991.74
in general payments reported to CMS, 2019-2025
41 companies · $2,724 in 2025
The $2,724 reported for 2025 was more than what 85% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,554 · 2020: $1,470 · 2021: $1,474 · 2022: $2,270 · 2023: $2,158 · 2024: $2,341 · 2025: $2,724.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,125 · Education: $99.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,124.94 |
| Education | $99.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,578.43 | 2019-2025 | |
| Boston Scientific Corporation | $1,494.46 | 2019-2025 | Exalt Model D, Axios |
| Janssen Biotech, INC. | $1,014.07 | 2019-2025 | Tremfya, Stelara, Simponi |
| Takeda Pharmaceuticals U.S.A., INC. | $976.29 | 2019-2025 | Entyvio, Eohilia, Gattex |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $810.19 | 2019-2025 | Xifaxan, Plenvu, Trulance |
| Genzyme Corporation | $589.74 | 2022-2025 | |
| Medtronic, INC. | $511.01 | 2021-2025 | Gi Genius, Nexpowder |
| Intercept Pharmaceuticals, INC. | $509.95 | 2019-2025 | Ocaliva |
| Regeneron Healthcare Solutions, INC. | $418.98 | 2022-2025 | Dupixent |
| Pfizer INC. | $353.55 | 2019-2025 | |
| Lilly USA, LLC | $294.45 | 2023-2025 | Omvoh |
| Ardelyx, INC. | $288.93 | 2023-2025 | Ibsrela |
| Ferring Pharmaceuticals INC. | $267.85 | 2020-2025 | Rebyota |
| Nestle Healthcare Nutrition INC. | $266.43 | 2021-2023 | |
| Allergan, INC. | $263.30 | 2019-2020 |
Show all 41 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vivus LLC | $261.66 | 2021-2024 | Qsymia |
| Qol Medical, LLC | $222.59 | 2019-2025 | Sucraid, Sucraid |
| Celgene Corporation | $189.67 | 2021-2023 | Zeposia |
| Aimmune Therapeutics, INC. | $178.92 | 2024 | |
| Gilead Sciences, INC. | $177.31 | 2019-2025 | Livdelzi |
| Medtronic USA, INC. | $148.19 | 2019 | |
| Conmed Corporation | $139.58 | 2025 | Conmed Hemostasis, Conmed Biliary |
| Ironwood Pharmaceuticals, INC | $139.09 | 2020-2024 | |
| Ethicon US, LLC | $125.00 | 2020 | |
| Madrigal Pharmaceuticals | $100.97 | 2025 | Rezdiffra |
| Phathom Pharmaceuticals, INC. | $77.18 | 2024-2025 | Voquezna |
| Janssen Scientific Affairs, LLC | $73.21 | 2024 | Stelara |
| Ucb, INC. | $71.54 | 2019-2020 | |
| Regeneron Pharmaceuticals, INC. | $59.71 | 2023 | Dupixent |
| Janssen Pharmaceuticals, INC | $58.96 | 2019 | |
| Mallinckrodt Hospital Products INC. | $58.25 | 2025 | Terlivaz |
| Merck Sharp & Dohme LLC | $49.11 | 2019-2022 | |
| Amgen INC. | $45.50 | 2025 | Uplizna |
| Biocon Biologics INC | $44.47 | 2025 | Hulio, Yesintek |
| Redhill Biopharma INC. | $28.94 | 2020-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $21.65 | 2023 | |
| Organon LLC | $18.55 | 2023 | Renflexis, Hadlima |
| Ipsen Biopharmaceuticals, INC | $18.11 | 2025 | Iqirvo |
| Shionogi INC | $16.09 | 2019 | |
| Evoke Pharma, INC. | $15.01 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $14.85 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nandhakumar Kanagarajan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.